On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > LATEST
LATEST
-
REGULATORY MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
-
COMMENTARY Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
-
ORGANIZATION JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
-
REGULATORY Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
-
ORGANIZATION Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
-
REGULATORY Latest Honebuto Draft Erases “Expansion” of CEA after LDP Pushback
June 12, 2025
-
REGULATORY LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
-
REGULATORY Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
-
REGULATORY Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
-
REGULATORY MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel Braced for Price Cuts after CEA
May 15, 2025
-
REGULATORY Chuikyo Plans Monthly Debates for CEA Reform in FY2026
May 15, 2025
-
REGULATORY Epkinly, Lunsumio to Face Price Cut of 2.7% under CEA Scheme
May 15, 2025
-
REGULATORY Industry Renews Opposition to CEA Expansion at LDP Hearing
May 13, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
ORGANIZATION PhRMA HTA Taskforce Warns CEA Expansion Will Accelerate Drug Loss in Japan
April 18, 2025
-
REGULATORY Chuikyo OKs Discussion Timeline for FY2026 Reimbursement Reform
April 10, 2025
-
REGULATORY MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
-
REGULATORY Litfulo’s Price to Be Trimmed 3.8% in June after CEA
March 13, 2025
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…